| Valuation method | Value, $ | Upside, % |
|---|---|---|
| Artificial intelligence (AI) | 43.60 | n/a |
| Intrinsic value (DCF) | 6.84 | n/a |
| Graham-Dodd Method | n/a | |
| Graham Formula | 0.64 | n/a |
Predictive Oncology Inc. (NASDAQ: POAI) is an AI-driven precision medicine company focused on revolutionizing cancer treatment through personalized therapies. Operating across four key segments—Helomics, zPREDICTA, Soluble, and Skyline—the company leverages artificial intelligence, 3D disease modeling, and proprietary biotech solutions to enhance drug discovery and diagnostic development. Helomics provides AI-powered tumor profiling and drug response testing, while zPREDICTA develops organ-specific 3D disease models for preclinical testing. Soluble specializes in protein stability and solubility solutions for biologics, and Skyline offers automated fluid waste management systems for healthcare settings. Headquartered in Eagan, Minnesota, Predictive Oncology serves biopharma, academic, and clinical research markets, positioning itself at the intersection of AI, oncology, and diagnostics. With a market cap under $10M, the company targets high-growth niches in the $200B+ global precision oncology market but faces significant commercialization challenges.
Predictive Oncology presents a high-risk, high-reward proposition for speculative investors. The company's AI-driven approach to cancer diagnostics and drug discovery addresses critical unmet needs in precision medicine, with potential long-term upside if its technologies gain clinical adoption. However, with negative EPS (-$2.32), declining revenue ($1.6M TTM), and substantial cash burn (-$10.9M operating cash flow), near-term viability depends on securing additional funding. The 1.3 beta indicates higher volatility than the market. While partnerships with pharma companies could validate its platforms, investors should weigh the promising technology against execution risks in a capital-intensive sector with formidable competitors like Exact Sciences and Guardant Health.
Predictive Oncology competes in fragmented but rapidly evolving segments of precision oncology. Its primary competitive advantage lies in the integration of AI with wet-lab capabilities across the drug development pipeline—from Helomics' patient-derived tumor data to zPREDICTA's 3D tissue models. This vertical integration differentiates POAI from pure-play AI diagnostics firms or traditional CROs. However, the company lacks the scale of established oncology diagnostics players (e.g., Exact Sciences' $1.7B revenue) or the clinical validation of liquid biopsy leaders like Guardant Health. In biopharma services, POAI's Soluble division competes with larger CDMOs but offers niche expertise in protein formulation. The Skyline segment's hospital equipment faces stiff competition from entrenched medical device manufacturers. POAI's technology partnerships (e.g., with UPMC) provide validation but haven't yet translated to commercial scale. With just $735K cash reserves against $2.1M debt, the company's ability to out-innovate better-funded rivals remains constrained unless additional capital is secured.